Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yolanda Sanchez

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of the National Cancer Institute|July 28, 2022
Leadership Diversity and Development in the Nation's Cancer CentersCaryn Lerman, Chanita Hughes-Halbert, Mary Falcone, et al.
Stem Cells (Dayton, Ohio)|May 26, 2012
High basal γH2AX levels sustain self-renewal of mouse embryonic and induced pluripotent stem cellsValentina Turinetto, Luca Orlando, Yolanda Sanchez-Ripoll, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 10, 2017
Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2<i>H</i>-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative StressJohn G Yonchuk, Joseph P Foley, Brian J Bolognese, et al.
Plos One|September 9, 2017
Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytesTimothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Plos One|November 3, 2017
Correction: Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytesTimothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Gut|April 5, 2015
Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartmentBruno Sainz, Sonia Alcala, Elena Garcia, et al.
Plos One|April 20, 2019
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel diseaseWilliam C Reisdorf, Qing Xie, Xin Zeng, et al.
Msystems|January 30, 2026
Gut microbiome signatures associated with depression and obesityCarlos Mora-Martínez, Gara Molina-Mendoza, María Carmen Cenit, et al.
Journal of Medicinal Chemistry|October 27, 2021
Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein-Protein InteractionDavid Norton, William G Bonnette, James F Callahan, et al.
Bioorganic & Medicinal Chemistry|January 11, 2019
Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivoJeffrey Boehm, Roderick Davis, Claudia E Murar, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|July 28, 2022
Leadership Diversity and Development in the Nation's Cancer CentersCaryn Lerman, Chanita Hughes-Halbert, Mary Falcone, et al.
Stem Cells (Dayton, Ohio)|May 26, 2012
High basal γH2AX levels sustain self-renewal of mouse embryonic and induced pluripotent stem cellsValentina Turinetto, Luca Orlando, Yolanda Sanchez-Ripoll, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 10, 2017
Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2<i>H</i>-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative StressJohn G Yonchuk, Joseph P Foley, Brian J Bolognese, et al.
Plos One|September 9, 2017
Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytesTimothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Plos One|November 3, 2017
Correction: Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytesTimothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Gut|April 5, 2015
Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartmentBruno Sainz, Sonia Alcala, Elena Garcia, et al.
Plos One|April 20, 2019
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel diseaseWilliam C Reisdorf, Qing Xie, Xin Zeng, et al.
Msystems|January 30, 2026
Gut microbiome signatures associated with depression and obesityCarlos Mora-Martínez, Gara Molina-Mendoza, María Carmen Cenit, et al.
Journal of Medicinal Chemistry|October 27, 2021
Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein-Protein InteractionDavid Norton, William G Bonnette, James F Callahan, et al.
Bioorganic & Medicinal Chemistry|January 11, 2019
Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivoJeffrey Boehm, Roderick Davis, Claudia E Murar, et al.
Pageof 7